Migraine drug that treats headache also eases symptoms like dizziness

Now it has been discovered that a medicine called Ubrogepant, which is already used to treat migraines, reduces the symptoms of non -headache that often achieved in the hours preceded by a migraine in itself, it is known that the symptom is known to work in these is known that it works in these it is known that it is known in these it is known that it is known that it works in these.

Before the weakening headache of a migraine, many people experience a prodrome phase where they obtain warning signs, such as sensitivity to light or sound, stiffness and neck stiffness, which can cause far -up in their life.

Migraña medicines developers have focused a lot on treating headache, and no therapy has been effective to relieve early symptoms of the thesis.

But UbrogaPant has proven promising to stop the headaches of the migraine if tasks are performed when the first symptoms hit, which leads Peter Goadsby to the King’s College London and his colleagues to look at the target, he can also dissipate thesis.

They conducted a study with 438 people, between 18 and 75, who had a history of migraines. Half of the participants touch a dose of 100 milligrams of Ubrogepant when they felt suggestion of symptoms that a headache per migraine was on its way, while the other half without knowing it touched a placebo. Then, the next time they hit the prodromic symptoms, the participants touch the opposite pill.

Apterteken Ubrogepant, self -informed improvements in their ability to concentrate an hour later, as well as a sensitivity reduced to light 2 hours later, and less fatigue and neck pain after 3 hours, compared to the experience when they put the placebo. Participants reported that nonsense and sound sensitivity are also lessons when they touch Ubrogepant.

“If they became Toy Ubrogepant, people were more likely to have a reduction in those non -painful symptoms, even before pain begins,” says Goadsby.

The study did not investigate the effect of medication in the aura, another characteristic of early migraine that involves sensory alterations that can affect vision, such as flashing lights and blind spots.

“Since common prodromic symptoms are often functionally disabling, the potential to intervene before in the migraine waterfall is clinically significant,” says Parisa Gazerani of the Metropolitan University of Oslo in Norway. More studies are needed to confirm that it is widely applicable, he thought, he adds.

“This research shows the potential of migraine treatments to reduce the early symptoms of the thesis, as well as the prevention of the main headache stage of an attack,” says Rob Music, who leads the confidence of migraine in the United Kingdom. “We hope to see more research in this area to help reduce the impact of migraine for 1 in 7 that lives with the condition.”